In a nutshell This study investigated if there is a higher risk of cardiovascular disease (CVD) in cancer survivors. They found that cancer survivors have a higher risk of CVD. Some background Improved cancer detection and treatment has increased the rates of survival. The number of cancer survivors living for more than 10 years is growing. Some...
Read MoreBreast cancer Posts on Medivizor
Looking for patients with advanced triple negative breast cancer to test a new treatment
In a nutshell This phase 1/2 trial is examining the effectiveness of treatment with GB1275 alone or in combination with immunotherapy in patients with solid tumors such as triple-negative breast cancer. The main outcome to be measured will be dose toxicity and tumor response to the treatment. This study is being conducted in Tennessee and Texas, US. The...
Read MoreTalazoparib before surgery for patients with BRCA mutated breast cancer
In a nutshell This study aimed to investigate the effectiveness and safety of talazoparib as a neoadjuvant agent (treatment before surgery) in patients with BRCA mutation and operable breast cancer. This study concluded that this treatment was a safe and effective in these patients. Some...
Read MoreSearching patients with breast cancer to test EndoPredict
In a nutshell This trial will evaluate a molecular test, EndoPredict®, in the treatment of breast cancer. The main outcome will be the adherence rate to EndoPredict® results. This trial is recruiting in South Carolina, USA. It is sponsored by Myriad Genetic Laboratories. The details Adjuvant chemotherapy (ACT) is...
Read MoreSide effects of ado-trastuzumab emtansine impacting outcomes in patients with HER2+ advanced breast cancer
In a nutshell This study aimed to investigate the impact of early side effects requiring ado-trastuzumab emtansine dose interruptions or reductions on outcomes for patients with HER2+ advanced metastatic breast cancer. This study concluded that these side effects do not impact the outcomes for these patients. Some background...
Read MoreStandard adjuvant chemotherapy versus capecitabine: longer follow up results in older breast cancer patients
In a nutshell This study aimed to investigate the outcomes of standard adjuvant chemotherapy versus capecitabine (Xeloda) in older patients with breast cancer after 10 years. This study concluded that with longer follow up, outcomes remained superior with standard adjuvant chemotherapy. Some...
Read MoreSearching for patients with advanced triple-negative breast cancer to test a new combination treatment
In a nutshell This phase 1b/2 trial will investigate the safety of cabozantinib (Cabometyx) with or without atezolizumab (Tecentriq) in patients with advanced solid tumors. The main outcomes will be maximum tolerated dose (MTD) and overall response rate (ORR). The details Advanced cancers have limited treatment options. Surgery may...
Read MoreHow effective is alpelisib in hormone-receptor positive breast cancer with PIK3CA-mutations?
In a nutshell This study investigated the effectiveness of alpelisib (Piqray) in hormone receptor-positive (HR+) -human epidermal growth factor receptor 2-negative (HER2-) breast cancer (BC). They found that alpelisib significantly improved survival in patients with PIK3CA mutations. Some background Breast cancer (BC) types can be...
Read MoreEvaluating a new drug combination with pertuzumab and subcutaneous trastuzumab
In a nutshell This study investigated if a combination including pertuzumab (Perjeta) and subcutaneous trastuzumab (Herceptin Hylecta) is safe in breast cancer (BC). They found that this combination was well tolerated in patients with HER2-positive BC. Some background Breast cancer (BC) is the most common cancer in...
Read MoreIs there an increased risk of fatigue and anemia after treatment with olaparib?
In a nutshell This study investigated the risk of fatigue and anemia with olaparib (Lynparza) treatment. The study found that there is an increased risk of fatigue and anemia with this treatment. Some background Breast cancer (BC) is the most common cancer affecting women. Some types of BC are caused by genetic mutations. These...
Read MoreSearching patients with triple-negative breast cancer to trial a new treatment combination
In a nutshell This phase 1b/2 trial will investigate the safety of treatment with rucaparib (Rubraca) in combination with other anti-cancer agents (ACAs) in patients with triple-negative breast cancer and other solid tumors. The main outcomes will be the number of treatment-related side effects and response to treatment. This trial is...
Read MoreLooking for patients with breast cancer to trial a new chemotherapy drug combined with targeted therapy
In a nutshell This phase 2 trial will investigate the effects of tesetaxel combined with targeted therapy drugs in advanced breast cancer (BC). The main outcomes will be the overall response rate (ORR) and progression-free survival (PFS). This trial is recruiting in Boston, MA and East Setauket, NY. The details Some...
Read More
